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Background:  Tolvaptan, an arginine vasopressin (AVP) antagonist, may be a novel therapy for congestive heart failure (CHF) but 
AVP activation is not uniform and results have been variable in previous trials of unselected CHF patients. Copeptin, c-terminal pre-
provasopressin, reflects AVP activation. We hypothesized patients with higher copeptin may respond better to tolvaptan.
methods:  This pilot study investigated 20 stable CHF outpatients (Pts) with reduced LVEF (≤40) selected by targeting upper or lower 
quartile copeptin levels at the screening visit (10 each). One 30 mg dose of tolvaptan was given with body weight, fluid intake and urine 
output monitored in a research unit for 24 hours. Inpatient copeptin levels were blinded until post study analysis. Pts were analyzed by a 
pre-specified baseline copeptin cut point (≥10 versus <10 pmol/L).
results:  Pts were 55% female, 55% African-American with serum sodium (mean±SD) 141±2.9 meq/L and serum creatinine 1.1±0.3 mg/
dL. Pts were on chronic diuretic (95% on loop daily dose furosemide equivalent 84±86 mg). There was a significant negative correlation 
between baseline copeptin and change in body weight (baseline to 24 hours) post tolvaptan (r=-0.47, p=0.039). Body weight declined more 
after tolvaptan in Pts with baseline copeptin ≥ 10 versus < 10 pmol/L.
conclusion:  These pilot results suggest a possible association between higher copeptin level and greater response to tolvaptan in CHF 
Pts with reduced LVEF. These findings warrant further investigation.
Changes in body weight and fluid status after tolvaptan by baseline copeptin
Study Group All Patients Copeptin ≥ 10 pmol/L Copeptin < 10 pmol/L *P value
N 20 10 10
Baseline Copeptin (pmol/L) 13.1 ± 9.7 20.5 ± 8.7 5.7 ± 1.9 <0.001
Change in Body Weight (Kg) -0.8 ± 1.1 -1.3 ± 1.0 -0.4 ± 1.0 0.035
Net Output (mL) 1360 ± 1881 2091 ± 1662 630 ± 1876 0.089
Total Output (mL) 6141 ± 2072 6498 ± 2328 5784 ± 1835 0.853
Total Input (mL) 4780 ± 1664 4406 ± 1398 5154 ± 1893 0.393
Values are mean ± SD. *P Values are for comparison of copeptin groups by nonparametric analysis.
